Business
Takeda bets USD 600 million on Insilico's generative AI platform for drug discovery
Takeda has struck a deal worth up to USD 600 million with Insilico Medicine (HKEX: 3696), gaining access to the company's Pharma.AI generative AI platform...
Abivax raises USD 800m in upsized offering to fund obefazimod US commercialization push
France-based Abivax SA (Euronext Paris / Nasdaq: ABVX) announced the pricing of an upsized underwritten public offering of American Depositary Shares,...
Oryzon secures EUR 37m as LSD1 inhibitor iadademstat advances
Spain-based Oryzon Genomics, S.A. (Madrid: ORY) announced a completed equity capital increase of EUR 12 million (approximately USD 14.1 million) alongside a...
Flare Therapeutics secures USD 85m Series C to advance prostate cancer degrader program
Cambridge, Massachusetts-based Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company focused on drugging transcription factors in...
Nuvectis replenishes coffers after Haisco deal with USD 100m public offering
Fort Lee, New Jersey-based Nuvectis Pharma, Inc. (Nasdaq: NVCT) announced the pricing of an underwritten public offering of common stock, raising USD 100...
FibroBiologics secures up to USD 9.0m in PIPE funds to extend runway
Houston-based FibroBiologics, Inc. (Nasdaq: FBLG) announced the closing of a private placement on June 29, 2026, raising USD 3.0 million in upfront gross...
Pyxis secures USD 114m to push MICVO toward dual clinical readouts in head and neck cancer
Boston-based Pyxis Oncology, Inc. (Nasdaq: PYXS) announced a private placement of up to USD 114 million to extend its cash runway into Q2 2027 and fund two...
Abivax raises USD 600m to fuel US launch of obefazimod ahead of NDA submission
France-based Abivax SA (Euronext Paris: ABVX / Nasdaq: ABVX) announced the launch of an underwritten public offering of approximately USD 600 million (EUR...
Hanmi completes USD 41m-backed acquisition of Aptose, securing tuspetinib AML program
South Korea-based Hanmi Pharmaceutical Co., Ltd. has completed its acquisition of Aptose Biosciences Inc. (TSX: APS | OTC: APTOF), a clinical-stage oncology...
Ipsen to acquire Memo Therapeutics for EUR 700m to gain first-in-class BK virus antibody
France-based Ipsen (Euronext: IPN; ADR: IPSEY) has agreed to acquire Switzerland-based Memo Therapeutics AG in a deal totaling more than EUR 700 million,...
Xellar closes USD 50m Series A to build AI-powered organ-on-chip drug discovery platform
Boston-based Xellar Biosystems has closed a USD 50 million Series A and A+ financing round to advance its organ-on-chip-based drug discovery platform, which...
METiS scores up to USD 1.62b from Deerfield's Boulevard Bio for preclinical trispecific TCE
Hong Kong-listed METiS TechBio (HKEX: 7666) has licensed its preclinical trispecific T-cell engager MTS-128 to Boulevard Bio, a Deerfield Management-backed...
Lilly outsources Verzenios commercialization in China to Innovent, deepening eight-deal partnership
Eli Lilly hands Innovent sole commercialization rights to abemaciclib in mainland China, deepening an eight-deal partnership as Lilly systematically...
Zymeworks acquires Theravance for USD 929m to secure Yupelri's USD 60m annual cash flows
Canada-based Zymeworks Inc. (Nasdaq: ZYME) has agreed to acquire Dublin-based Theravance Biopharma, Inc. (Nasdaq: TBPH) for USD 17.00 per share in cash,...
Talawar's SPAC merger secures USD 285m to advance dual-pathway atopic dermatitis bispecific
New York-based Talawar Therapeutics has announced a definitive business combination agreement with JATT II Acquisition Corp (Nasdaq: JATT), a Cayman...
The AllSci Brief
Systematic R&D and deal news. Daily.